izpis_h1_title_alt

Psoralen derivatives as inhibitors of mycobacterium tuberculosis proteasome
ID Rožman, Kaja (Author), ID Alexander, Evan M. (Author), ID Ogorevc, Eva (Author), ID Bozovičar, Krištof (Author), ID Sosič, Izidor (Author), ID Aldrich, Courtney C. (Author), ID Gobec, Stanislav (Author)

.pdfPDF - Presentation file, Download (6,28 MB)
MD5: A0CF9586CFB79249DCD04C788F7D6B3E
URLURL - Source URL, Visit https://www.mdpi.com/1420-3049/25/6/1305 This link opens in a new window

Abstract
Protein degradation is a fundamental process in all living organisms. An important part of this system is a multisubunit, barrel-shaped protease complex called the proteasome. This enzyme is directly responsible for the proteolysis of ubiquitin- or pup-tagged proteins to smaller peptides. In this study, we present a series of 92 psoralen derivatives, of which 15 displayed inhibitory potency against the Mycobacterium tuberculosis proteasome in low micromolar concentrations. The best inhibitors, i.e., 8, 11, 13 and 15, exhibited a mixed type of inhibition and overall good inhibitory potency in biochemical assays. N-(cyanomethyl)acetamide 8 (K$_i$ = 5.6 µM) and carboxaldehyde-based derivative 15 (K$_i$ = 14.9 µM) were shown to be reversible inhibitors of the enzyme. On the other hand, pyrrolidine-2,5-dione esters 11 and 13 irreversibly inhibited the enzyme with K$_i$ values of 4.2 µM and 1.1 µM, respectively. In addition, we showed that an established immunoproteasome inhibitor, PR-957, is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K$_i$ = 5.2 ± 1.9 µM, k$_{inact}$/K$_i$ = 96 ± 41 M$^{−1}$·s$^{−1}$). These compounds represent interesting hit compounds for further optimization in the development of new drugs for the treatment of tuberculosis.

Language:English
Keywords:protein degradation, proteasome, Mycobacterium tuberculosis, psoralens, nonpeptidic proteasome inhibitors
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:14 str.
Numbering:Vol. 25, iss. 6, art. 1305
PID:20.500.12556/RUL-133422 This link opens in a new window
UDC:547.96.057:615.4
ISSN on article:1420-3049
DOI:10.3390/molecules25061305 This link opens in a new window
COBISS.SI-ID:4894321 This link opens in a new window
Publication date in RUL:26.11.2021
Views:845
Downloads:176
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Molecules
Shortened title:Molecules
Publisher:MDPI
ISSN:1420-3049
COBISS.SI-ID:18462981 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:12.03.2020

Secondary language

Language:Slovenian
Keywords:sinteza beljakovin, zaviralci Mycobacterium tuberculosis, imunoproteasom, farmacevtska kemija, beljakovine

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:Other - Other funder or multiple funders
Funding programme:Republic of Slovenia, Ministry of Education, Science and Sports
Project number:C3330-17-529028

Funder:Other - Other funder or multiple funders
Funding programme:Republic of Slovenia, Ministry of Education, Science and Sports
Project number:Raziskovalci-2.0-UL-FFA-529028

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back